Global PERFORMA Phase 3 trial in MASH progressing as planned Positive RECLAIM Phase 2 data in AUD highlighted in a late-breaking oral presentation at AASLD The Liver Meeting® 2026 End-of-Phase 2 meeting with FDA for AUD program scheduled for December 2026 $480 million in cash, cash equivalents and investments as of September 30, 2026 Webcast to be held today at 8:30 a.m. ET MORRISTOWN, N.J.
Significant reductions across non-invasive measures of liver fat, inflammation and fibrosis observed at 48 weeks of pemvidutide treatment, with generally favorable tolerability profile
Results from RECLAIM Phase 2 study show treatment with pemvidutide led to significant reduction in heavy drinking days and improved outcomes on other key clinical measures in patients with AUD; generally favorable tolerability profile
First presentation at a scientific conference of key data from RECLAIM, a multicenter Phase 2 trial of a balanced 1:1 glucagon/GLP-1 receptor agonist in alcohol use disorder (AUD)
Board appointments align with successful transition to late-stage clinical Company developing pemvidutide as a differentiated liver franchise with multiple potential indications As part of this transition, John M. Gill, Mitchel Sayare, Ph.D.
GAITHERSBURG, Md., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on Wednesday, September 30, 2026, at 10:30 a.m. ET.
GAITHERSBURG, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Thursday, September 10, 2026, at 9:30 a.m. ET.
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.